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Human papillomavirus (HPV) infection causes cervical cancer and premalignant dysplasia. Type-specific HPV prevalence data provide
a basis for assessing the impact of HPV vaccination programmes on cervical cytology. We report high-risk HPV (HR-HPV) type-
specific prevalence data in relation to cervical cytology for 24 510 women (age range: 20–64; mean age 40.2 years) recruited into the
ARTISTIC trial, which is being conducted within the routine NHS Cervical Screening Programme in Greater Manchester. The most
common HR-HPV types were HPV16, 18, 31, 51 and 52, which accounted for 60% of all HR-HPV types detected. There was a
marked decline in the prevalence of HR-HPV infection with age, but the proportion due to each HPV type did not vary greatly with
age. Multiple infections were common below the age of 30 years but less so between age 30 and 64 years. Catch-up vaccination of
this sexually active cohort would be expected to reduce the number of women with moderate or worse cytology by 45%, but the
number with borderline or mild cytology would fall by only 7%, giving an overall reduction of 12% in the number of women with
abnormal cytology and 27% in the number with any HR-HPV infection. In the absence of broader cross-protection, the large majority
of low-grade and many high-grade abnormalities may still occur in sexually active vaccinated women.
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Human papillomavirus (HPV) infection has a central role in the
aetiology of cervical cancer (Walboomers et al, 1999). More than
100 HPV types have been described (de Villiers et al, 2004) and 40
can infect the anogenital tract. Genital HPV types are categorised
according to their association with cervical cancer (Munoz et al,
2003). About 20 are classified as high-risk (HR) types and are
associated with cervical cancer and precancerous lesions, as well as
low-grade cervical pathology. Worldwide, HPV types 16 and 18
cause approximately 70% of cervical cancers; HPV types 31, 33, 35,
45, 52 and 58 account for an additional approximately 20% of
cases, although there is substantial geographical variation in the
relative frequency of different HR types (Clifford et al, 2005). Low-
risk HPV types, including HPV6 and 11, cause low-grade cervical
lesions, genital warts and recurrent respiratory papillomatosis.
In 2006, a quadrivalent prophylactic vaccine against HPV types
6, 11, 16 and 18 was licensed in the United States (FDA, 2006) and
Europe (EMEA, 2006). More recently, the bivalent vaccine against
HPV types 16 and 18 has been approved in Europe (EMEA, 2007).
Prophylactic HPV vaccination of young female adolescents has
been approved as a public health policy in the United Kingdom
and other countries, and data on the type-specific prevalence of
HPV infection are relevant in assessing its potential impact on
cervical pathology and screening.
A Randomised Trial in Screening to Improve Cytology
(ARTISTIC) is being conducted within the routine NHS Cervical
Screening Programme in Greater Manchester to evaluate
the effectiveness of HPV testing in primary cervical screening.
The randomised comparison will determine whether combining
HPV testing with liquid-based cytology offers added sensitivity
over cytology alone and, if so, whether this would be cost-effective.
Our first report described the baseline prevalence of HPV16, 18
and all other HR-HPV types in relation to age, cytology and
histology (Kitchener et al, 2006). We now report type-specific
prevalence data for all HR-HPV types in relation to cervical
cytology and age.
MATERIALS AND METHODS
High-risk HPV detection
After processing for cytology, residual ThinPreps liquid-based
cytology samples were sent to the Virology Laboratory at
Manchester Royal Infirmary. High-risk HPV detection was carried
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out using the Digene Hybrid Capture 2s (hc2) test according
to the manufacturer’s instructions, as described previously
(Kitchener et al, 2006). A positive hc2 result was defined as
RLU/CoX1, according to the manufacturer’s criteria at the start of
the study. Residual cells from all liquid-based cytology samples
were pelleted and stored at 701C.
HPV polymerase chain reaction and genotyping
Genotyping of all hc2-positive samples was carried out using the
prototype Roche Line Blot Assay (LBA). Polymerase chain reaction
(PCR) amplification and product detection for 37 anogenital types
were essentially performed as described previously (Peyton et al,
2001). Following DNA extraction from a 50 ml volume of the stored,
pelleted sample using the Roche MagNA Pure automated system, a
50 ml volume of extracted DNA was added to an equal volume of
reaction mixture containing 10 mM Tris-HCl (pH 8.5), 50 mM KCl,
4 mM MgCl2, 500 nM each of biotinylated HPV primers PGMY09
and PGMY11, 25 nM each of biotinylated human beta-globin
primers PC04 and GH20, 200 mM each of nucleotides dATP, dCTP
and dGTP, 600 mM of nucleotide dUTP and 7.5 U of Amplitaq Gold.
Following heating at 951C to activate the Amplitaq Gold
polymerase enzyme and render the native DNA single stranded,
nucleic acid was amplified by 40 cycles of 951C/30 s to allow strand
denaturation, 551C/1 min for primer annealing and 721C/1 min for
primer extension. This cycling program was followed by an
elongated primer extension period of 56 min at 721C. Amplified
product was stored at 41C. Following denaturation, amplified
product was hybridised to oligonucleotide-coated genotyping
strips before colour development and interpretation using the
template provided.
Due to the unexpectedly large number of hc2-positive LBA-
negative samples, a subset (n¼ 102) of these samples was
examined using GP5þ /6þ PCR (de Roda Husman et al, 1995).
The PCR product was visualised after electrophoresis through a 2%
agarose gel and ethidium bromide staining.
Cytology
All cytology was read independently of the HPV results. Slides
were read according to the routine laboratory protocol and
reported as such. There was no attempt to reach consensus for any
of the smear grades. There has been no post hoc review of cytology.
National guidelines were adhered to, which meant that high-grade
abnormalities, that is, moderate and severe dyskaryosis, were
referred for colposcopy and biopsy. In women with low-grade
abnormalities, that is, borderline and mild dyskaryosis, cytology
was repeated at 6 months with referral to colposcopy if the
abnormality persisted.
RESULTS
A total of 24 510 eligible women had satisfactory cytology and
HPV results by hc2 at entry. Samples from 3813 women (15.6% of
all eligible women) were HPV-positive by hc2, but 40 (1.0%) of
these either gave negative results for beta-globin gene amplifica-
tion and were reported as inhibitory or were of insufficient
volume for further testing. These 40 were excluded, and all the
results were based on the remaining 24 470 women. Crossreactivity
with low-risk or HR types not included in the hc2 probe mix was
observed in 417 (11.1%) hc2-positive samples. A broad range of
HPV type crossreactivity occurred. This was particularly notice-
able for HPV types 53, 66 and 70, which were frequently detected.
A further 772 (20.5%) hc2-positive samples did not hybridise to
any of the LBA probes. These 1189 samples were classified as hc2
positive but HR-HPV negative. The remaining 2584 hc2-positive
samples (68.5%) were positive by LBA for one or more of the 13
HR types included in the hc2 HR probe mix. Of those hc2-positive
samples giving a low RLU/Co value between 1 and 3, 26.7%
contained an hc2 HR type; 16.2% crossreacted with other types
and 57.1% failed to type. The corresponding figures of those hc2-
positive samples giving a high RLU/Co value of X100 were 91.9,
4.8 and 3.3%. In total, 50% of hc2-positive LBA-negative
samples had an RLU/Co value between 1 and 2.11. On testing a
subset of 102 hc2-positive LBA-negative samples by GP5þ /6þ
PCR, 39.2% were found to be HPV positive. Multiple HR-HPV
types were detected in 680 (18.0% of hc2-positive samples) and
infection with a single HR-HPV type was detected in 1904 (50.5%)
samples.
Prevalence rates for each HR-HPV type are shown in Table 1,
both overall and by age group. The most common genotype
at all ages was HPV16 (overall prevalence 3.3%), followed by HPV
types 52 (1.5%), 18 and 31 (both 1.3%), 51 (1.2%) and 39 (1.1%).
There was a marked decline in the prevalence of HR-HPV with age,
both overall (27.3% below age 30 years and 6.1% at age 30 years or
above) and for each HPV type, but less so for hc2-positive samples
in which no HR-HPV was detected (6.4% of women aged below 30
years and 4.5% aged 30 –64 years).
The HPV prevalence rates by age group and cytology are shown
in Table 2 for HPV16, HPV18 without HPV16 and for other HR-
HPVs combined. Below age 30 years, a high proportion of infected
women carried two or more different HR-HPV types (44% of
women with HPV16, 50% with HPV18 but not HPV16 and 24% of
all women with other HR-HPVs). Multiple infections were less
common at age 30–64 years (23% of women with HPV16, 20%
with HPV18 and 14% of women with other HR-HPVs).
The proportion with moderate dyskaryosis or worse was 15.3%
(396 out of 2584) in women with any HR-HPV infection, 1.2% for
hc2 positives with no HR-HPVs and 0.22% for hc2-negative
women. The risk of moderate or worse cytology was highest in
women infected with HPV16 irrespective of the presence of
other HPVs (26.2% for HPV16 alone, 25.3% together with other
HR-HPVs).
Cytology by HPV status is shown in Table 3 for women aged
20–29 years, 30–64 years and overall. Summing up the number of
different HR-HPV types detected in each woman for the
denominator, the proportion of all detected infections that were
due to each HPV type did not vary greatly with age. Below age 30
years, 24.0% (499 out of 2077) of HR-HPV infections were due to
HPV16, compared with 21.3% (306 out of 1435) at age 30– 64 years
(P¼ 0.06). The corresponding proportions were 6.3 and 3.7% for
HPV33 (P¼ 0.001), 2.4 and 4.1% for HPV35 (P¼ 0.003) and 4.5
and 6.7% for HPV45 (P¼ 0.005). No other type showed significant
variation with age. The proportion of women with a single
HR-HPV type who had moderate or worse cytology (Table 3;
extreme right column) was 26% for HPV16, between 12 and 19%
for HPV types 18, 31, 33 and 58, 7 –9% for types 35, 45, 51 and 52,
and less than 5% for types 39, 56, 59 and 68. The proportion with
borderline or mild cytology was much less variable, ranging from
23 to 42%. The proportion of different grades of cytology positive
for HPV types 16, 18, 31, 45 and 52 are shown in Figure 1. This
graphically demonstrates the increasing prevalence with cytology
grade.
Of the CIN2þ lesions found before the exit round, 108 out of
329 (33%) and 83 out of 225 (37%), respectively, were identified
in high- and low-grade cytological abnormalities, which were
HR-HPV positive but types 16/18 negative.
DISCUSSION
The ARTISTIC trial cohort (see Appendix for ARTISTIC Trial
Study Group) is the first large population of women in the United
Kingdom to have undergone HPV testing and genotyping.
Although from a limited geographic area, the setting in primary
Type-specific prevalence: ARTISTIC trial data
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care makes this a representative population of women across the
cervical screening age range. Several conclusions can be inferred
from the distributions of each HR-HPV type in relation to age and
the cytological findings presented here. The high proportion of
women with abnormal cytology who are HR-HPV positive but
HPV16/18 negative is clinically significant, as it accounts for 35%
(33% of moderate or worse and 37% of borderline or mild) of all of
CIN2þ lesions.
The five most prevalent types (16, 18, 31, 51 and 52) together
account for 60% of the 3512 HR-HPV infections detected (Table 3);
HPV16 and 18 account for 32%. The overall prevalence of HR-HPV
infection decreased sharply with age, from 27% below age 30 to
10% at age 30–39 years, 4.2% at 40–49 years and 2.5% at 50– 64
years. The prevalence in Manchester between 1988 and 1993 was
about 40% lower at each age (16% at age 20–29 years and less than
3% above age 40 years) (Peto et al, 2004). The difference in
prevalence may be due to lower assay sensitivity or suboptimal
specimen collection and storage methods employed in the earlier
study. Alternatively or additionally, changes in the prevalence of
genital HPV infections as suggested by increased UK diagnosis of
genital warts between 1972 and 2005 (Health Protection Report,
2007) may be relevant. However, changes in clinical practices in
the diagnosis and reporting of genital warts may further
complicate the picture. The difference in prevalence between
young and older women is less marked in most other countries
(Franceschi et al, 2006). Most HR-HPV types show a similar age
distribution, with relatively minor differences in the type
distribution above and below the age of 30 years. The most
marked difference was shown by HPV33, being detected in 9.3% of
women with HR-HPV below age 30 years and only 4.5% at older
ages (Table 3; Po0.001).
The failure of the LBA to confirm that 31.5% of the hc2-positive
samples contain hc2 HR-HPV types is a cause of concern,
especially if this assay was to be used as a frontline screening
Table 2 Prevalence of single and multiple infections with HPV16, 18 and other HR-HPV types by age group and cytology result
HPV16 HPV18 not 16 HPV16 and/or 18 hc2 positive
No. of women
Single
HR-HPV
n (%)
Multiple
HR-HPV
n (%)
Single
HR-HPV
n (%)
Multiple
HR-HPV
n (%)
No other
HR n (%)
Other
HR n (%)
HR-HPV,
not 16/18
n (%)
HR-HPV
n (%)
No HR
HPV
n (%)
hc2 negative
n (%)
Age
20–29 5150 280 (5.4) 219 (4.3) 77 (1.5) 78 (1.5) 374 (7.3) 280 (5.4) 750 (14.6) 1404 (27.3) 329 (6.4) 3417 (66.3)
30–39 7599 158 (2.1) 49 (0.6) 65 (0.9) 17 (0.2) 225 (3.0) 64 (0.8) 490 (6.5) 779 (10.3) 368 (4.8) 6452 (84.9)
40–49 6111 51 (0.8) 11 (0.2) 15 (0.2) 3 (0.1) 68 (1.1) 12 (0.2) 179 (2.9) 259 (4.2) 270 (4.4) 5582 (91.3)
50–64 5610 27 (0.5) 10 (0.2) 14 (0.2) 3 (0.05) 43 (0.8) 11 (0.2) 88 (1.6) 142 (2.5) 222 (4.0) 5246 (93.5)
Cytology
Negative 21 364 235 (1.1) 85 (0.4) 96 (0.5) 47 (0.2) 340 (1.6) 123 (0.6) 807 (3.8) 1270 (6.0) 940 (4.4) 19 154 (89.7)
B/M 2650 146 (5.5) 131 (4.9) 53 (2.0) 41 (1.6) 210 (7.9) 161 (6.1) 547 (20.6) 918 (34.6) 235 (8.9) 1497 (56.5)
Mod+ 456 135 (29.6) 73 (16.0) 22 (4.8) 13 (2.9) 160 (35.1) 83 (18.2) 153 (33.6) 396 (86.8) 14 (3.1) 46 (10.1)
Total 24 470 516 (2.1) 289 (1.2) 171 (0.7) 101 (0.4) 710 (2.9) 367 (1.5) 1507 (6.2) 2584 (10.6) 1189 (4.9) 20 697 (84.6)
B/M¼ borderline/mild dyskaryosis; HR-HPV¼ high-risk human papillomavirus; Mod+¼moderate dyskaryosis or worse.
Table 1 Prevalence of HR-HPVs overall and as a proportion of HR-HPV-positive women by age group
20–29 years 30–39 years 40–49 years 50–64 years All ages
Type n
% of
all
women
% of
HR-HPV+
women n
% of
all
women
% of
HR-
HPV+
women n
% of
all
women
% of
HR-
HPV+
women n
% of
all
women
% of
HR-
HPV+
women n
% of
all
women
% of
HR-
HPV+
women
16 499 9.7 35.5 207 2.7 26.6 62 1.0 23.9 37 0.7 26.1 805 3.3 31.2
18 191 3.7 13.6 89 1.2 11.4 20 0.3 7.7 19 0.3 13.4 319 1.3 12.3
31 185 3.6 13.2 102 1.3 13.1 27 0.4 10.4 12 0.2 8.5 326 1.3 12.6
33 130 2.5 9.3 41 0.5 5.3 10 0.2 3.9 2 0.04 1.4 183 0.7 7.1
35 49 1.0 3.5 39 0.5 5.0 17 0.3 6.6 3 0.1 2.1 108 0.4 4.2
39 159 3.1 11.3 75 1.0 9.6 17 0.3 6.6 15 0.3 10.6 266 1.1 10.3
45 94 1.8 6.7 58 0.8 7.4 20 0.3 7.7 18 0.3 12.7 190 0.8 7.4
51 189 3.7 13.5 73 1.0 9.4 26 0.4 10.0 17 0.3 12.0 305 1.2 11.8
52 211 4.1 15.0 106 1.4 13.6 39 0.6 15.1 11 0.2 7.8 367 1.5 14.2
56 98 1.9 7.0 58 0.8 7.4 13 0.2 5.0 13 0.2 9.2 182 0.7 7.0
58 97 1.9 6.9 46 0.6 5.9 18 0.3 7.0 7 0.1 4.9 168 0.7 6.5
59 125 2.4 8.9 40 0.5 5.1 23 0.4 8.9 11 0.2 7.8 199 0.8 7.7
68 50 1.0 3.6 30 0.4 3.9 8 0.1 3.1 6 0.1 4.2 94 0.4 3.6
16 and/or 18 654 12.7 46.6 289 3.8 37.1 80 1.3 30.9 54 0.96 38.0 1077 4.4 41.7
Any HR-HPV 1404 27.3 100 779 10.3 100 259 4.2 100 142 2.5 100 2584 10.6 100
hc2+ No HR-HPV 329 6.4 — 368 4.8 — 270 4.4 — 222 4.0 — 1189 4.9 —
hc2 3417 66.4 — 6452 84.9 — 5582 91.3 — 5246 93.5 — 20 697 84.6 —
All women 5150 100 — 7599 100 — 6111 100 — 5610 100 — 24 470 100 —
HR-HPV¼ high-risk human papillomavirus.
Type-specific prevalence: ARTISTIC trial data
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test. This is due, in part, to the demonstrated crossreaction of the
hc2 test with other putative HR as well as low-risk types. However,
the fact that 20.5% failed to yield any detectable HPV type is more
problematic. As the whole of the PGMY-amplified product
generated during LBA testing was denatured, further analysis by
gel electrophoresis was not possible. Further work using another
well-documented primer system (GP5þ /6þ PCR) followed by
gel electrophoresis suggested that 39.2% of these hc2-positive
LBA-negative samples might in fact contain HPV. Confirmation of
this observation would require further analysis on a larger number
of samples. The 13% originally selected merely provides an insight
into the true HPV status of these samples. The use of the improved,
commercially available linear array assay (Coutlee et al, 2006) to
confirm these hc2-positive samples should improve the confirma-
tory rate. There would still remain a substantial number of samples
that do not appear to contain a demonstrable HPV genotype.
Approximately half of these samples give an hc2 RLU value
between 1 and 2 providing further evidence that it may be
Table 3 Cytology by HPV status
HPV type
Cytology
20–29 years 30–64 years All ages
1904 women with a
single HPV infection
Negative B/M* Mod+* Negative B/M Mod+ Negative B/M Mod+ Total Negative B/M Mod+
16 184 202 113 136 75 95 320 (39.8%) 277 (34.4%) 208 (25.8%) 805 (100%) 235 (45.5%) 146 (28.3%) 135 (26.2%)
18 93 74 24 67 41 20 160 (50.2%) 115 (36.1%) 44 (13.8%) 319 (100%) 96 (56.1%) 53 (31.0%) 22 (12.9%)
31 83 67 35 62 46 33 145 (44.5%) 113 (34.7%) 68 (20.9%) 326 (100%) 97 (53.3%) 53 (29.1%) 32 (17.6%)
33 45 58 27 21 22 10 66 (36.1%) 80 (43.7%) 37 (20.2%) 183 (100%) 32 (41.6%) 31 (40.3%) 14 (18.2%)
35 23 20 6 28 25 6 51 (47.2%) 45 (41.7%) 12 (11.1%) 108 (100%) 31 (52.5%) 23 (39.0%) 5 (8.5%)
39 67 71 21 56 38 13 123 (46.2%) 109 (41.0%) 34 (12.8%) 266 (100%) 78 (60.5%) 46 (35.7%) 5 (3.9%)
45 47 33 14 58 28 10 105 (55.3%) 61 (32.1%) 24 (12.6%) 190 (100%) 59 (64.8%) 24 (26.4%) 8 (8.8%)
51 70 99 20 63 40 13 133 (43.6%) 139 (45.6%) 33 (10.8%) 305 (100%) 83 (50.6%) 69 (42.1%) 12 (7.3%)
52 96 88 27 82 57 17 178 (48.5%) 145 (39.5%) 44 (12.0%) 367 (100%) 105 (56.1%) 68 (36.4%) 14 (7.5%)
56 43 46 9 40 38 6 83 (45.6%) 84 (46.2%) 15 (8.2%) 182 (100%) 48 (53.3%) 38 (42.2%) 4 (4.4%)
58 40 45 12 32 24 15 72 (42.9%) 69 (41.1%) 27 (16.1%) 168 (100%) 49 (57.6%) 24 (28.2%) 12 (14.1%)
59 69 44 12 46 20 8 115 (57.8%) 64 (32.2%) 20 (10.1%) 199 (100%) 74 (69.8%) 27 (25.5%) 5 (4.7%)
68 27 19 4 27 13 4 54 (57.4%) 32 (34.0%) 8 (8.5%) 94 (100%) 34 (72.3%) 11 (23.4%) 2 (4.3%)
16 and/or 18 265 260 129 198 111 114 463 (39.8%) 371 (34.4%) 243 (22.6%) 1077 (100%) — — —
Any HR-HPV 651 556 197 619 362 199 1270 (43.0%) 918 (35.5%) 396 (15.3%) 2584 (100%) — — —
hc2+ No
HR-HPV
236 88 5 704 147 9 940 (49.1%) 235 (19.8%) 14 (1.2%) 1189 (100%) — — —
hc2 3119 286 12 16 035 1211 34 19 154 (79.1%) 1497 (7.2%) 46 (0.22%) 20 697 (100%) — — —
All women 4006 930 214 17 358 1720 242 21 364 (92.5%) 2650 (10.8%) 456 (1.9%) 24 470 (100%) 1021 613 270
No. of HR-HPVs
detected
887 866 324 718 467 250 1605 1333 574 3512 1021 613 270
B/M¼ borderline/mild dyskaryosis; HR-HPV¼ high-risk human papillomavirus; Mod+¼moderate dyskaryosis or worse. Results by age (20–29, 30–64 years), overall, and in
1904 women with a single HPV type.
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advisable to raise the hc2 cutoff level, as has been suggested
previously (Hesselink et al, 2006). A recent study also found that a
number of hc2-positive samples do not contain HR types when
tested by the LBA, particularly those having low RLU values
(Castle et al, 2008).
Differences in the relative frequencies of different HPV types are
seen both between and within continents. The gross international
differences between HPV subtypes (Yamada et al, 1997) indicate
that infections often involve viruses that have evolved in the region
over many centuries, but now there is substantial intercontinental
mixing through increased migration. Among HR-HPV-positive
women with normal cytology, the relative frequencies for several of
the common HPV types were similar to those in other European
countries, as reported by Clifford et al (2005), although the
proportion in our study was substantially greater for HPV52 and
for the combined total of types 39, 51, 59 and 68. In a recent study
of urine samples from American women aged 18–25 years, the
distribution between the 13 HR-HPVs detected by hc2 was also
similar to that seen in Manchester, with HPV16 being twice as
prevalent as any other type, followed by types 51, 52, 39, 59 and 18
(Manhart et al, 2006). A strikingly different distribution was
recently reported among 1921 American women aged 14–59 years,
with HPV types 52, 59 and 51 being more common than HPV16
(Dunne et al, 2007). Although the prototype Roche LBA was used
in both studies, the variation in type distribution observed may
reflect the different sample types used, self-sampling cervico-
vaginal specimens being used in the US study.
The proportion of women with HPV16 who had borderline or
mild cytology was increased by the presence of other HR-HPVs
(Table 2; 28.3% for single infections and 45.3% for multiple
infections), but the proportion with moderate or worse cytology
was not (26.2% for single infections and 25.3% for multiple
infections). This suggests that HPV16 may compete with less
virulent types in the progression to neoplasia rather than in the
normal infective process.
The data in Table 2 provide a basis for modelling the overall
effect of vaccination on cervical cytology. The simplest assumption
is that elimination of HPV16 and 18 would give women with either
or both of these viruses, but no other HR-HPVs, the cytological
profile of those with no HR-HPVs, with 5% remaining hc2 positive
and the remainder becoming hc2 negative, whereas those also
infected with other HR-HPVs would move to the category of
HR-HPV without HPV16 or 18. Based on this, the number with
moderate or worse cytology would be reduced by 45% in a
population with this age distribution, but the number with
borderline or mild cytology would fall by only 7%, giving an
overall reduction of 12% in the number with abnormal cytology
and reducing the number with any HR-HPV by 27%. The cost-
benefit balance of vaccination would of course be greatly improved
if a polyvalent vaccine reduced the risk to a level where it would be
safe to carry out routine screening for vaccinated women less
frequently.
The impact of vaccination on cytological abnormality rates will
be considerably less in women aged over 30 years, as a far lower
proportion of low-grade cytological abnormalities are HR-HPV-
positive in older women. Human papillomavirus types 16 and/or
18 were detected in 260 out of 930 (28%) women aged below 30
years with low-grade (borderline or mild) cytology, and in only 111
out of 1720 (6.5%) aged 30–64 years. In the absence of broader
cross-protection, the large majority of low-grade and many high-
grade abnormalities would still occur in vaccinated women. This is
consistent with the data emerging from clinical trials of
prophylactic vaccine, which show much greater efficacy in
preventing CIN2þ than for low-grade abnormalities. Potential
cross-protection involving HPV31 and 45 has been demonstrated
by Harper et al, 2006. Effective cross-protection involving these
types could prevent a significant further proportion of both low-
and high-grade abnormalities, particularly among women below 30
years, although this needs to be borne out in ongoing clinical trials.
So far only limited data are available regarding the effects of cross-
protection in relation to clinical outcome (Brown et al, 2007). The
extent to which vaccines directed against types 16 and 18 would
prevent abnormalities associated with non-vaccine types as part of
a multiple infection is not yet clear. Only 57% of infections due to
HPV16 or 18 in low-grade cytology, and 66% in high-grade
cytology, involved no other HR-HPVs.
More detailed age-specific analysis of these data will help to
validate models of the possible impact of vaccination on subsequent
cervical screening before long-term follow-up of current trial
cohorts. The follow-up of ARTISTIC patients to the subsequent
routine screening rounds will also provide estimates of type-specific
risk over 3–6 years in women with normal baseline cytology.
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